BRAF and neoplasm: One possibility is the heterodimerization of BRAF with CRAF, a BRAF isoform, which drives increased Ras–MAPK signalling76, and has been noted in the development of resistance and secondary tumours following BRAF inhibition in metastatic melanoma77,.78